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ABSTRACT
Little has been documented about hypersensitivity reactions caused by treatment with rivaroxaban. This paper reports a bullous 
pemphigoid-like skin eruption that occurred in a 76-year-old female patient during rivaroxaban treatment. This case highlights the vigilance 
required by healthcare workers in recognising potential adverse effects of newly marketed drugs and in making medication changes when 
necessary. A bullous pemphigoid-like eruption due to treatment with rivaroxaban has not, to the best of the Authors’ knowledge, been 
reported previously in the literature.
LEARNING POINTS
• Rivaroxaban can cause a bullous eruption apparently similar to epithelial toxic necrolysis (or to Stevens-Johnson syndrome).
• There is an apparent similarity between skin adverse events caused by the different anticoagulants.
•	 The	anticoagulant	responsible	for	the	skin	side-effects	can	be	identified	on	clinical	grounds	by	the	correct	differential	diagnosis.
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INTRODUCTION
Cutaneous drug eruptions are among the most common adverse drug reactions and may often represent a challenging diagnostic problem. 
While	a	single	drug	can	elicit	a	range	of	reaction	patterns,	no	reaction	pattern	is	specific	to	a	particular	drug.	Although	the	temporal	link	
between initiation of drug therapy and the onset of a drug rash is critical for the diagnosis, drug reactions may also occur during chronic drug 
administration. 
Blisters are a well-known manifestation of cutaneous reactions to drugs. In many types of drug reactions, bullae and vesicles may be found in 
addition to other manifestations. Bullae are usually noted in erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, 
urticaria, vasculitis, porphyria cutanea tarda, and phototoxic reactions[1]. Although drug-induced bullous pemphigoid eruptions are rare, 
they can be caused by certain drugs, such as furosemide, heparin, ibuprofen, captopril, and many others[2-6]. 
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Rivaroxaban (Xarelto®, Bayer Corporation, Pittsburgh, PA) is a new oral anticoagulant drug. It acts as a direct factor Xa inhibitor and is used 
in venous thromboembolism prophylaxis. This drug is increasingly prescribed because, as an oral drug, it is easily handled during therapy; 
moreover, no coagulation monitoring is needed, and it has a wide therapeutic index. However, phase III studies have listed hypersensitivity 
to rivaroxaban as ‘undetermined’[7].
CASE DESCRIPTION
A	76-year-old	female	patient	with	a	medical	history	of	paroxysmal	atrial	fibrillation	and	depression	was	hospitalised	on	10	January	2016	
due to a pulmonary thromboembolism. During hospitalisation, the patient started sertraline 100 mg daily, rivaroxaban 20 mg daily, and 
furosemide 10 mg twice daily. Fifteen days after the start of therapy, the patient developed a rash characterised by urticarial plaques on her 
back, upper limbs, and anterior surfaces of her thighs. In addition, tense, sero-haemorrhagic blisters developed on both legs (Figs. 1 and 2). 
No lesions were observed on mucosae. 
The patient was followed in the Internal Medicine and Dermatology Service. The tentative diagnosis was that of a bullous pemphigoid 
secondary to drug use or neoplastic aetiology. Given the known association between furosemide and bullous pemphigoid, its use was 
discontinued and the patient started on therapy using a topical corticosteroid, betamethasone cream, twice a day.
The results on the patient’s diagnostic exams were as follows: a WBC of 7220 with 14.4% eosinophils, platelets 197,000/µl, and ESR 60 mm/
hr. The CEA, Ca 15-3, Ca 19-9, and Ca 125 results were within normal ranges. The search for anti-skin, anti-basement, epidermal membrane 
and	 anti-keratinocyte	 autoantibodies	 (indirect	 immunofluorescence	 [IIF]	 in	 peripheral	 blood)	 was	 negative.	 Histological	 examination	
disclosed	 intraepidermal	 blistering	with	 eosinophils	 and	 apoptotic	 keratinocytes	 inside,	with	 significant	 spongiosis	 in	 the	 neighbouring	
epidermis (Fig. 3).	Discrete	infiltrates	of	eosinophils	were	diffusely	represented	among	spongiotic	areas	and	throughout	the	upper	part	of	
the	dermis	in	a	perivascular	and	interstitial	infiltrate	pattern	(Fig. 4).	Immunofluorescence	was	negative	for	IgA,	IgG,	IgM,	C3,	and	C1q.
Two weeks after the use of furosemide had been discontinued, the cutaneous condition worsened; bullous lesions now appeared on the 
forearms (Fig. 5). At that time, rivaroxaban was discontinued and replaced with warfarin, while furosemide was reintroduced. A rapid 
improvement in the lesions was noted within 1 week, and no relapse occurred during the 12-month follow-up.
Figure 1. Bullous pemphigoid-like skin eruption on the legs Figure 2. Bullous pemphigoid-like skin eruption on the legs 
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DISCUSSION
The diagnosis of bullous pemphigoid-like skin eruption due to rivaroxaban was established. Our differential diagnoses included haemorrhagic 
toxic necrolysis / heparin-induced thrombocytopenia and Stevens-Johnson syndrome (Table 1). However, the patient’s normal platelet 
count,	 negative	Nikolsky’s	 sign,	 results	 on	 the	 direct	 immunofluorescence	 test,	 bullous	 eruption	 in	 the	 dermis-epidermis	 junction,	 and	
histologic	findings	ruled	out	these	diagnoses.	Histologically,	drug-induced	variants	of	bullous	pemphigoid	are	similar	to	the	typical	form	and	
are characteristically composed of eosinophil-rich subepidermal blisters[8]. In the initial stage, only eosinophilic spongiosis and numerous 
dermal eosinophils are present, with eosinophils lining up along the basement membrane[9]. At later stages, the blisters may appear to be 
intraepidermal as a result of keratinocyte regeneration. In the present case, these various morphological features were present and, in 
a	concordant	clinical	context,	were	diagnostic	 for	 the	disease.	Negative	 immunofluorescence	studies,	as	 in	 this	case,	occur	 in	4%	of	 the	
patients with bullous pemphigoid[1, 8].
Cutaneous reactions have been reported during anticoagulant therapy with coumarin derivatives and with unfractionated and low-
molecular-weight heparins and heparinoids[10-12]. However, very few data regarding hypersensitivity reactions to rivaroxaban are available; 
Figure 3. Histological examination using H&E staining and low power magnification 
revealed intraepidermal blistering
Figure 4. Histological examination using H&E staining and medium power magnification 
revealed eosinophils in tiny collections that were abundantly present among spongiotic 
areas in the epidermis (arrow) and throughout the upper part of the dermis (arrowhead)
Figure 5. Bullous pemphigoid-like skin eruption on forearm
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we	were	 only	 able	 to	 find	 two	 such	 cases	 in	 the	 literature[13, 14]. Even though heparins, warfarin, and rivaroxaban have very different 
mechanisms of action, the clinical similarity of their epithelial side-effects is remarkable. In spite of this similarity, a differential diagnosis 
between	the	offending	agents	can	be	made	with	high	confidence	(Table 2).
Steven-Johnson syndrome 
(SJS)
Bullous pemphigoid Haemorragic skin eruptions
Idiopathic Drug-induced Heparin-induced 
skin necrosis
Coumarin-induced 
skin necrosis
Clinical 
features
• Rusty macules with 
or without epidermal 
detachment (<10% BSA)
• Atypical target lesions 
(papular lesions with two 
zones of colour changes, 
with papular, vesicular or 
flaccid bullous centre)
• Multiple tense bullae arising on normal or 
erytemathous skin
• Bullae can rupture, leaving circular erosions with 
haemorragic crusts
• Urticarial papules and plaques, along with bullae 
containing serous fluid
• Pruritus and nonspecific eczematous lesions can 
precede
• At least 50% of patients have peripheral 
eosinophilia
• Often associated 
with heparin-induced 
thrombocytopenia 
with thrombosis
• Necrosis starts with a 
small, erythematous 
and painful lesion that 
later extends to areas 
of necrosis
Pain, oedema and small 
subcutaneous 
haematoma, followed 
by erythematous or 
haemorrhagic changes in 
demarcated lesions that 
become bullous and can 
progress to gangrenous 
necrosis
Mucosal 
involvement
Severe Rare No
Distribution
Face, neck, trunk Lower abdomen, thighs, forearms, legs Injection site, but can also be 
generalised
Subcutaneous fatty tissue, eg 
breasts, thighs, abdomen 
and buttocks
Histological 
findings
• Subepidermal blister 
with overlyng confluent 
necrosis of the entire 
epidermis; keratinocyte 
apoptosis is a hallmark of 
SJS
• Sparse perivascular 
infiltrate composed 
primarily of lymphocytes
• Subepidermal bullae
• Infiltrate composed 
of neutrophils and 
eosinophils in the 
dermis and bulla 
cavity
Subepidermal bulla or 
intraepidermic
Microvascular thrombi 
in small vessels with 
minimal inflammation
Areas with thrombosis, 
microvascular injury 
and fibrin deposits in the 
postcapillary veins and 
small vessels
Presence 
of 
autoantibodies
Negative • DIF with IgG and/or 
C3 in the basement 
membrane zone
• IIF (+) in 70% of 
patients
DIF and IIF can be 
negative
Antibodies against heparin 
platelet factor-4 
complexes
Others
•      Systemic symptoms are 
usually present (fever, 
hepatitis, cytopenias)
•     Progression to toxic 
epidermal necrolysis is 
possible
•     Nikolsky (+/-)
Nikolsky (-) Platelet count drops by 50% 
compared with the 
baseline value within 
first 10–14 days of 
treatment
• 10 days after the onset of 
therapy
• Protein C or protein S 
deficiencies
Table 1. Differential diagnosis of a bullous skin eruption in patients undergoing anticoagulant therapy
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Substance group according to site of action Chemical name Bullous skin reaction
Vitamin K antagonists Coumarins • Haemorrhagic bullous eruption
• Skin necrosis
Antithrombin-III activators  (heparins) Glycosaminoglycans • Haemorrhagic bullous eruption
• Bullous-like eruption
• Stevens–Johnson syndrome / Toxic epidermal 
necrolysis
• Bulbous pemphigoid
• Skin necrosis
Direct factor Xa inhibitors Xabans Toxic skin eruption
Table 2. Bullous skin reactions to various substance groups with anticoagulant effects
